

David A Bond

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7550882/publications.pdf>

Version: 2024-02-01

46
papers

698
citations

567281

15
h-index

610901

24
g-index

47
all docs

47
docs citations

47
times ranked

1073
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1750-1753.	1.3	1
2	CAR T-cell therapy for B-cell lymphoma. <i>Current Problems in Cancer</i> , 2022, 46, 100826.	2.0	26
3	Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 342.e1-342.e5.	1.2	5
4	Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e435-e442.	0.4	6
5	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	1.4	59
6	Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study. <i>Haematologica</i> , 2021, 106, 1932-1942.	3.5	21
7	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.	7.2	45
8	Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. <i>Journal of Clinical Medicine</i> , 2021, 10, 1207.	2.4	11
9	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1648-1659.	5.2	28
10	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	2.2	3
11	The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. <i>Blood</i> , 2021, 138, 2372-2382.	1.4	35
12	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	5.2	24
13	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	5.2	21
14	Analysis of Outcomes and Predictors of Response in Patients with Relapsed Mantle Cell Lymphoma Treated with Brexucabtagene Autoleucel. <i>Blood</i> , 2021, 138, 1756-1756.	1.4	6
15	Feasibility of High-dose Methotrexate Administered on Day 1 of (R)CHOP in aggressive non-Hodgkin Lymphomas. <i>Blood Advances</i> , 2021, , .	5.2	7
16	Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib. <i>Blood</i> , 2021, 138, 3731-3731.	1.4	3
17	Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution. <i>Blood</i> , 2021, 138, 3851-3851.	1.4	1
18	Outcomes of Patients with Diffuse Large B Cell and High-Grade B Cell Lymphomas with Synchronous CNS and Systemic Involvement at Diagnosis Treated with High-Dose Methotrexate and R-CHOP: A Single-Center Retrospective Study. <i>Blood</i> , 2021, 138, 1425-1425.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. <i>Cancer</i> , 2020, 126, 293-303.	4.1	18
20	Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. <i>Blood Advances</i> , 2020, 4, 4648-4652.	5.2	53
21	Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 903-921.	2.2	17
22	Second cancer incidence in CLL patients receiving BTK inhibitors. <i>Leukemia</i> , 2020, 34, 3197-3205.	7.2	45
23	<p>Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6573-6581.	2.0	10
24	Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics. <i>Blood Advances</i> , 2020, 4, 253-262.	5.2	29
25	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Blood</i> , 2020, 136, 2-3.	1.4	1
26	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. <i>Blood</i> , 2020, 136, 24-26.	1.4	0
27	Prognostication, Survival and Treatment-Related Outcomes in HIV-Associated Burkitt Lymphoma (HIV-BL): A US and UK Collaborative Analysis. <i>Blood</i> , 2020, 136, 49-50.	1.4	1
28	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. <i>Blood</i> , 2020, 136, 4-6.	1.4	0
29	A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. <i>Blood</i> , 2020, 136, 29-29.	1.4	2
30	Targeting BTK in CLL: Beyond Ibrutinib. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 197-205.	2.3	98
31	Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. <i>Journal of Clinical Oncology</i> , 2019, 37, 471-480.	1.6	74
32	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019, 134, 397-397.	1.4	3
33	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402.	1.4	9
34	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. <i>Blood</i> , 2019, 134, 775-775.	1.4	5
35	Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 753-753.	1.4	9
36	Short Time to Treatment Is Associated with Inferior Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3997-3997.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 3483-3483.	1.4	1
38	Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine + Rituximab without Autologous Transplant. <i>Blood</i> , 2019, 134, 1525-1525.	1.4	10
39	A Phase I Study of Nivolumab and Lenalidomide in Relapsed/ Refractory B Cell Lymphoma. <i>Blood</i> , 2019, 134, 4091-4091.	1.4	3
40	The Impact of Pre-Diagnosis Tobacco Use in Mantle Cell Lymphoma. <i>Blood</i> , 2019, 134, 5891-5891.	1.4	0
41	Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 4571-4571.	1.4	1
42	North American Practice Patterns for PET-2 Positive Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1553-1553.	1.4	0
43	Outcomes of Patients with Limited-Stage Aggressive Large B-Cell Lymphoma with MYC Rearrangement with and without BCL2 and/or BCL6 Rearrangements: A Retrospective Analysis from 15 US Academic Centers. <i>Blood</i> , 2018, 132, 451-451.	1.4	3
44	Outcome of Patients with Aggressive B Cell Lymphomas Who Receive Second-Line Salvage Immunochemotherapy Following Treatment Failure of Intensive First-Line Immunochemotherapy. <i>Blood</i> , 2018, 132, 453-453.	1.4	1
45	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 4153-4153.	1.4	0
46	Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 1589-1597.	1.3	2